These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31797240)

  • 41. Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies.
    Barbieri L; Verdoia M; Schaffer A; Suryapranata H; De Luca G
    Cardiovasc Drugs Ther; 2016 Dec; 30(6):611-622. PubMed ID: 27757726
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint.
    Wernly B; Rezar R; Gurbel P; Jung C
    J Thromb Thrombolysis; 2020 Jan; 49(1):173-176. PubMed ID: 31686298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of Efficacy and Safety of Anticoagulant Monotherapy and Combined Therapy of Anticoagulant and Antiplatelets in Patients With Stable Coronary Artery Disease and Atrial Fibrillation: A Meta-Analysis.
    Tentu N; Ijaz A; Batool S; Khan RS; Mohammed F; Khan MH; Sandhu QI; Ali N
    Cureus; 2022 Sep; 14(9):e29772. PubMed ID: 36324348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Saito Y; Kobayashi Y
    J Cardiol; 2019 Jan; 73(1):1-6. PubMed ID: 30293674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
    Manzano-Fernández S; Pastor FJ; Marín F; Cambronero F; Caro C; Pascual-Figal DA; Garrido IP; Pinar E; Valdés M; Lip GYH
    Chest; 2008 Sep; 134(3):559-567. PubMed ID: 18641090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified.
    Andrade JG; Deyell MW; Wong GC; Macle L
    Can J Cardiol; 2018 Nov; 34(11):1426-1436. PubMed ID: 30404748
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.
    Lip GY; Laroche C; Popescu MI; Rasmussen LH; Vitali-Serdoz L; Dan GA; Kalarus Z; Crijns HJ; Oliveira MM; Tavazzi L; Maggioni AP; Boriani G
    Europace; 2015 Dec; 17(12):1777-86. PubMed ID: 26321406
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role.
    Alexopoulos D; Vlachakis P; Lekakis J
    Cardiovasc Drugs Ther; 2017 Jun; 31(3):319-324. PubMed ID: 28643219
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey.
    Lane DA; Dagres N; Dan GA; García Seara J; Iliodromitis K; Lenarczyk R; Lip GYH; Mansourati J; Marín F; Scherr D; Potpara TS
    Europace; 2019 Jul; 21(7):1116-1125. PubMed ID: 30874724
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
    Angiolillo DJ; Goodman SG; Bhatt DL; Eikelboom JW; Price MJ; Moliterno DJ; Cannon CP; Tanguay JF; Granger CB; Mauri L; Holmes DR; Gibson CM; Faxon DP
    Circulation; 2018 Jul; 138(5):527-536. PubMed ID: 30571525
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
    Bennaghmouch N; de Veer AJWM; Bode K; Mahmoodi BK; Dewilde WJM; Lip GYH; Brueckmann M; Kleine E; Ten Berg JM
    Circulation; 2018 Mar; 137(11):1117-1129. PubMed ID: 29101289
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis.
    Fanaroff AC; Hasselblad V; Roe MT; Bhatt DL; James SK; Steg PG; Gibson CM; Ohman EM
    Int J Cardiol; 2017 Aug; 241():87-96. PubMed ID: 28320608
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study.
    Chen PC; Lip GY; Yeh G; Lin HJ; Chien KL
    PLoS One; 2015; 10(4):e0125257. PubMed ID: 25923742
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antithrombotic Therapy for Chronic Kidney Disease Patients With Concomitant Atrial Fibrillation and Coronary Artery Disease.
    Lee KH; Ou SM; Chu YC; Lin YP; Tsai MT; Tarng DC
    Front Cardiovasc Med; 2021; 8():751359. PubMed ID: 34692798
    [No Abstract]   [Full Text] [Related]  

  • 56. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
    Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual-Antithrombotic Therapy With DOACs After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
    Shurrab M; Danon A; Alnasser S; Glover B; Kaoutskaia A; Henderson M; Newman D; Crystal E; Ko D
    Can J Cardiol; 2020 Jan; 36(1):135-142. PubMed ID: 31874747
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
    Alamneh EA; Chalmers L; Bereznicki LR
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
    Ten Berg JM; de Veer A; Oldgren J; Steg PG; Zateyshchikov DA; Jansky P; Seung KB; Hohnloser SH; Lip GYH; Nordaby M; Kleine E; Bhatt DL; Cannon CP;
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2331-2341. PubMed ID: 31806214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.